JP2010519204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519204A5 JP2010519204A5 JP2009549625A JP2009549625A JP2010519204A5 JP 2010519204 A5 JP2010519204 A5 JP 2010519204A5 JP 2009549625 A JP2009549625 A JP 2009549625A JP 2009549625 A JP2009549625 A JP 2009549625A JP 2010519204 A5 JP2010519204 A5 JP 2010519204A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- aryl
- heteroaryl
- heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 59
- 125000003118 aryl group Chemical group 0.000 claims 26
- 125000001072 heteroaryl group Chemical group 0.000 claims 26
- 125000000623 heterocyclic group Chemical group 0.000 claims 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- -1 heterocyclealkyl Chemical group 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims 12
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000000304 alkynyl group Chemical group 0.000 claims 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 6
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 6
- 125000001624 naphthyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 claims 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 claims 3
- QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 claims 3
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000001363 autoimmune Effects 0.000 claims 3
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims 3
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 3
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 3
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims 3
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000001786 isothiazolyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000005494 pyridonyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004419 alkynylene group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 108010068370 Glutens Proteins 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010021067 Hypopituitarism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 230000006044 T cell activation Effects 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000021312 gluten Nutrition 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940124452 immunizing agent Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000017983 photosensitivity disease Diseases 0.000 claims 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000005057 thyrotoxicosis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- AEWDLXUAHPHIPM-UHFFFAOYSA-N COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c(cc3)ccc3F)c2cc1 Chemical compound COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c(cc3)ccc3F)c2cc1 AEWDLXUAHPHIPM-UHFFFAOYSA-N 0.000 description 1
- WVXAYXKCTSNEDD-UHFFFAOYSA-N COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c(cc3F)cc(F)c3F)c2cc1 Chemical compound COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c(cc3F)cc(F)c3F)c2cc1 WVXAYXKCTSNEDD-UHFFFAOYSA-N 0.000 description 1
- JPNCSUACTCRKEU-UHFFFAOYSA-N COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c3cc4ccccc4[s]3)c2cc1 Chemical compound COc1cc2nccc(OCCN(C(C=C3)=O)N=C3c3cc4ccccc4[s]3)c2cc1 JPNCSUACTCRKEU-UHFFFAOYSA-N 0.000 description 1
- POWQKVGHPULXHD-UHFFFAOYSA-N C[n]1ncc(C(C=C2)=NN(CCOc3c(ccc(OC)c4)c4ncc3)C2=O)c1 Chemical compound C[n]1ncc(C(C=C2)=NN(CCOc3c(ccc(OC)c4)c4ncc3)C2=O)c1 POWQKVGHPULXHD-UHFFFAOYSA-N 0.000 description 1
- LVPPGKJARBYRFE-UHFFFAOYSA-N Cc1cc(C(C=C2)=NN(CCOc3c(ccc(OC)c4)c4ncc3)C2=O)ncc1 Chemical compound Cc1cc(C(C=C2)=NN(CCOc3c(ccc(OC)c4)c4ncc3)C2=O)ncc1 LVPPGKJARBYRFE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90203007P | 2007-02-16 | 2007-02-16 | |
| PCT/US2008/002007 WO2008103277A2 (en) | 2007-02-16 | 2008-02-15 | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010519204A JP2010519204A (ja) | 2010-06-03 |
| JP2010519204A5 true JP2010519204A5 (enExample) | 2012-04-05 |
Family
ID=39563458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549625A Pending JP2010519204A (ja) | 2007-02-16 | 2008-02-15 | 窒素含有複素環ケトン類およびそれらのｃ−Ｍｅｔ阻害薬としての使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8314087B2 (enExample) |
| EP (1) | EP2114898A2 (enExample) |
| JP (1) | JP2010519204A (enExample) |
| AU (1) | AU2008219166B2 (enExample) |
| CA (1) | CA2676173A1 (enExample) |
| MX (1) | MX2009008531A (enExample) |
| WO (1) | WO2008103277A2 (enExample) |
Families Citing this family (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5580732B2 (ja) | 2007-04-03 | 2014-08-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 置換ベンゼン殺菌・殺カビ剤 |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| EP2226320A4 (en) * | 2007-12-26 | 2012-07-11 | Eisai R&D Man Co Ltd | PROCESS FOR THE PRODUCTION OF A HETEROCYCLE-SUBSTITUTED PYRIDINE DERIVATIVE |
| DE102008019907A1 (de) * | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| CN103951643B (zh) | 2008-07-25 | 2015-12-09 | 盐野义制药株式会社 | 用作hiv整合酶抑制剂的化合物 |
| JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な化合物 |
| KR101678563B1 (ko) | 2008-12-11 | 2016-11-22 | 비이브 헬쓰케어 컴퍼니 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체 |
| KR101733625B1 (ko) | 2008-12-11 | 2017-05-10 | 시오노기세야쿠 가부시키가이샤 | 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성 |
| BRPI0924084B1 (pt) | 2008-12-19 | 2021-12-21 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina e composição farmacêutica que os compreende |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| TW201124078A (en) | 2009-12-22 | 2011-07-16 | Du Pont | Fungicidal 2-(bicyclic aryloxy) carboxamides |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ |
| US20130116231A1 (en) * | 2010-07-12 | 2013-05-09 | Merck Sharp & Dohme Corp. | Tyrosine kinase inhibitors |
| JP2013536802A (ja) * | 2010-08-31 | 2013-09-26 | メルク・シャープ・エンド・ドーム・コーポレイション | チロシンキナーゼ阻害剤 |
| AR082912A1 (es) | 2010-09-08 | 2013-01-16 | Sumitomo Chemical Co | Metodo para producir compuestos de piridazinona y un intermediario de sintesis |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| WO2012087372A1 (en) | 2010-12-22 | 2012-06-28 | E. I. Du Pont De Nemours And Company | Fungicidal 2-(bicyclic aryloxy)carboxamides |
| CN102558147B (zh) * | 2010-12-23 | 2014-09-17 | 江苏先声药物研究有限公司 | 化合物、制备方法及应用 |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| IN2014CN02501A (enExample) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
| MX2014003796A (es) | 2011-09-30 | 2015-01-16 | Vertex Pharma | Compuestos utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr). |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841449B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2013075084A1 (en) * | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9206128B2 (en) * | 2011-11-18 | 2015-12-08 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US20140044802A1 (en) | 2012-04-05 | 2014-02-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| DK3628670T3 (da) | 2012-04-13 | 2022-12-05 | Epizyme Inc | Saltform til ezh2-hæmning |
| UA112897C2 (uk) | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
| CN105102432B (zh) | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| SMT202000713T1 (it) | 2012-12-07 | 2021-03-15 | Vertex Pharma | Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro |
| MX2015008444A (es) | 2012-12-28 | 2015-09-23 | Dow Agrosciences Llc | Derivados de n-(sustituido)-5-flouro-4-imino-3-metil-2-oxo-3,4-dih idropirimidin-1 (2h)-carboximida. |
| JP6336480B2 (ja) * | 2012-12-28 | 2018-06-06 | アダマ・マクテシム・リミテッド | １−（置換ベンゾイル）−５−フルオロ−４−イミノ−３−メチル−３，４−ジヒドロピリミジン−２（１ｈ）−オンの誘導体 |
| AU2013370493B2 (en) | 2012-12-28 | 2017-08-17 | Adama Makhteshim Ltd. | N-(substituted)-5-fluoro-4-imino-3-methyl-2-oxo-3,4-dihydropyrimidine-1 (2H)-carboxylate derivatives |
| KR102309245B1 (ko) | 2012-12-31 | 2021-10-06 | 아다마 마켓심 리미티드 | 살진균제로서의 3-알킬-5-플루오로-4-치환된-이미노-3,4-디히드로피리미딘-2(1h)-온 유도체 |
| CA2900652C (en) | 2013-02-15 | 2021-05-04 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| CN107915751A (zh) | 2013-02-20 | 2018-04-17 | 卡拉制药公司 | 治疗性化合物和其用途 |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| WO2014151142A1 (en) | 2013-03-15 | 2014-09-25 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| AU2014306149B2 (en) | 2013-08-06 | 2019-09-19 | Imago Biosciences Inc. | KDM1A inhibitors for the treatment of disease |
| WO2015023915A1 (en) | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
| US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
| KR20160068956A (ko) | 2013-10-15 | 2016-06-15 | 얀센 파마슈티카 엔.브이. | RORyT의 퀴놀리닐 조절제 |
| EP3057962B1 (en) | 2013-10-16 | 2023-10-18 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| DK3290407T3 (da) | 2013-10-18 | 2020-03-23 | Celgene Quanticel Res Inc | Bromodomæneinhibitorer |
| WO2015066482A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3066098A1 (de) | 2013-11-08 | 2016-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte uracile und ihre verwendung |
| US9695131B2 (en) | 2013-11-08 | 2017-07-04 | Bayer Pharma Aktiengesellschaft | Substituted uracils as chymase inhibitors |
| HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
| CA2936551A1 (en) | 2014-01-24 | 2015-07-30 | Confluence Life Sciences, Inc. | Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases |
| WO2015112847A1 (en) * | 2014-01-24 | 2015-07-30 | Confluence Life Sciences, Inc. | Arylpyridinone itk inhibitors for treating inflammation and cancer |
| US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
| CN107074863B (zh) | 2014-06-05 | 2019-12-03 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
| PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
| ES2896400T3 (es) | 2014-08-01 | 2022-02-24 | Nuevolution As | Compuestos activos frente a bromdominios |
| CN106573898B (zh) | 2014-08-14 | 2018-11-09 | 豪夫迈·罗氏有限公司 | 治疗和预防乙型肝炎病毒感染的新的哒嗪酮和三嗪酮 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| HK1245677A1 (zh) | 2015-01-23 | 2018-08-31 | Aclaris Therapeutics, Inc. | 用於治疗炎症和癌症的杂环itk抑制剂 |
| KR102626978B1 (ko) | 2015-02-12 | 2024-01-18 | 이마고 바이오사이언시즈 인코포레이티드 | 질환 치료를 위한 kdm1a 저해제 |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| SG10201912684TA (en) * | 2015-06-25 | 2020-03-30 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for fibrosis |
| WO2017019489A1 (en) | 2015-07-24 | 2017-02-02 | George Robert Pettit | Quinstatin compounds |
| CA2994478C (en) | 2015-08-12 | 2023-10-03 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
| US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| KR102678021B1 (ko) | 2015-09-30 | 2024-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물 |
| US20190112317A1 (en) | 2015-10-05 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies |
| PE20181197A1 (es) | 2015-10-14 | 2018-07-23 | Bristol Myers Squibb Co | 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj) |
| ES2854733T3 (es) | 2015-12-16 | 2021-09-22 | Bristol Myers Squibb Co | Heteroarilhidroxipirimidinonas como agonistas del receptor APJ |
| TWI744301B (zh) | 2016-03-24 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺 |
| US11390590B2 (en) | 2016-08-16 | 2022-07-19 | Imago Biosciences, Inc. | Methods and processes for the preparation of KDM1A inhibitors |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| MX2019002629A (es) | 2016-09-08 | 2019-10-07 | Kala Pharmaceuticals Inc | Formas cristalinas de compuestos terapéuticos y usos de los mismos. |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| EP3532467A1 (en) * | 2016-10-26 | 2019-09-04 | Proteostasis Therapeutics, Inc. | Pyridazine derivatives, compositions and methods for modulating cftr |
| WO2018077227A1 (zh) | 2016-10-27 | 2018-05-03 | 福建广生堂药业股份有限公司 | 作为c-MET抑制剂的吡啶酮类化合物 |
| US10316038B2 (en) | 2017-01-25 | 2019-06-11 | Aclaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer |
| EP3655396A1 (en) | 2017-07-17 | 2020-05-27 | Adama Makhteshim Ltd. | Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| KR102684364B1 (ko) | 2018-05-11 | 2024-07-11 | 이마고 바이오사이언시즈 인코포레이티드 | 질환의 치료를 위한 kdm1a 저해제 |
| WO2019236625A1 (en) * | 2018-06-04 | 2019-12-12 | Ohio State Innovation Foundation | Eaat2 activators and methods of using thereof |
| BR112021008905A2 (pt) | 2018-11-06 | 2021-08-10 | Edgewise Therapeutics, Inc. | compostos de piridazinona e usos dos mesmos |
| KR102885525B1 (ko) | 2018-11-06 | 2025-11-13 | 엣지와이즈 테라퓨틱스, 인크. | 피리다지논 화합물 및 이의 용도 |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN111393375A (zh) * | 2020-04-07 | 2020-07-10 | 中国药科大学 | 一种氮取代的六元芳杂环酮类化合物及其药物组合物、制备方法和用途 |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2023189602A1 (ja) | 2022-03-30 | 2023-10-05 | 石原産業株式会社 | ピリダジノン系化合物又はその塩及びそれらを含有する有害生物防除剤 |
| KR20250040894A (ko) | 2022-05-25 | 2025-03-25 | 이케나 온콜로지, 인코포레이티드 | Mek 억제제 및 이의 용도 |
| CN117510470A (zh) * | 2022-07-27 | 2024-02-06 | 暨南大学 | 哒嗪酮类化合物及其应用 |
| CN115872976B (zh) * | 2022-12-30 | 2024-05-14 | 中国药科大学 | 一种喹啉衍生物、含有其的药物组合物及其用途 |
| WO2025153721A1 (en) * | 2024-01-19 | 2025-07-24 | Scenic Biotech Bv | Pla2g15 inhibitors |
| CN121064162B (zh) * | 2025-11-05 | 2026-01-30 | 中国药科大学 | 一类2-(2-(喹啉-4-基氧)乙基)哒嗪-3(2h)-酮化合物及其制备方法和应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3009A (en) * | 1843-03-21 | Lard-lamp | ||
| US3956287A (en) * | 1973-11-07 | 1976-05-11 | Richardson-Merrell Inc. | 7-[(2-Oxo-1-pyridinyl)acylamino]cephalosporin derivatives |
| CH629240A5 (de) * | 1976-09-02 | 1982-04-15 | Henkel Kgaa | Mittel zum faerben von keratinhaltigem material. |
| US4673735A (en) * | 1982-04-15 | 1987-06-16 | Sandoz Ltd. | Azo compounds having at least one 6-hydroxypyrid-2-one coupling component radical metal complexes thereof and intermediates therefor |
| EP0092520B1 (de) * | 1982-04-15 | 1986-11-12 | Sandoz Ag | Basische Verbindungen, deren Herstellung und Verwendung |
| JP2762522B2 (ja) | 1989-03-06 | 1998-06-04 | 藤沢薬品工業株式会社 | 血管新生阻害剤 |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5892112A (en) | 1990-11-21 | 1999-04-06 | Glycomed Incorporated | Process for preparing synthetic matrix metalloprotease inhibitors |
| FR2670208B1 (fr) | 1990-12-07 | 1993-08-13 | Pf Medicament | Derives de phenyl-1 dihydro 1-4 arylalcoylamino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique. |
| CZ403592A3 (en) * | 1992-02-20 | 1993-12-15 | Hoechst Ag | Arylcarbonylaminoalkyldihydrooxopyridines, process of their preparation and their use |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| PT669929E (pt) | 1992-11-13 | 2007-04-30 | Immunex Corp | Ligando de elk, uma citoquina |
| BR9307570A (pt) * | 1992-12-02 | 1999-05-25 | Pfizer | Diéteres de catecol como inibidores seletivos de pdeiv |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| AU702522B2 (en) | 1994-04-15 | 1999-02-25 | Amgen, Inc. | HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases |
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| US5919905A (en) | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US6057124A (en) | 1995-01-27 | 2000-05-02 | Amgen Inc. | Nucleic acids encoding ligands for HEK4 receptors |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2324846T3 (es) | 1998-03-04 | 2009-08-17 | Bristol-Myers Squibb Company | Inhibidores de la proteina tirosina quinasa de imidazopirazina heterociclo-sustituida. |
| IL139934A0 (en) | 1998-05-29 | 2002-02-10 | Sugen Inc | Pyrrole substituted 2-indolinone derivatives and pharmaceutical compositions containing the same |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| CA2336848A1 (en) | 1998-07-10 | 2000-01-20 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| EP1109555A4 (en) | 1998-08-31 | 2001-11-21 | Merck & Co Inc | Novel angiogenesis inhibitors |
| CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Healthcare Llc | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| TW506993B (en) * | 1999-03-15 | 2002-10-21 | Ciba Sc Holding Ag | Reactive dyes, processes for their preparation and process for dyeing or printing a fibre material |
| JP4673977B2 (ja) | 1999-03-30 | 2011-04-20 | ノバルティス アーゲー | 炎症性疾患治療用フタラジン誘導体 |
| ES2219290T3 (es) * | 1999-03-30 | 2004-12-01 | Ciba Specialty Chemicals Holding Inc. | Colorantes reactivos, procedimiento para su preparacion y su empleo. |
| ATE324444T1 (de) | 1999-06-07 | 2006-05-15 | Immunex Corp | Tek-antagonisten |
| US6521424B2 (en) | 1999-06-07 | 2003-02-18 | Immunex Corporation | Recombinant expression of Tek antagonists |
| CN100376567C (zh) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
| DK1233943T3 (da) | 1999-11-24 | 2011-08-15 | Sugen Inc | Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander |
| US6515004B1 (en) | 1999-12-15 | 2003-02-04 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6727225B2 (en) | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
| EP1259595B1 (en) | 2000-02-25 | 2007-04-04 | Immunex Corporation | Integrin antagonists |
| DE60125026T2 (de) | 2000-03-23 | 2007-06-28 | Takeda Pharmaceutical Co. Ltd. | Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung |
| JP2001335579A (ja) * | 2000-03-23 | 2001-12-04 | Takeda Chem Ind Ltd | フロイソキノリン誘導体、その製造法および用途 |
| US6630500B2 (en) | 2000-08-25 | 2003-10-07 | Cephalon, Inc. | Selected fused pyrrolocarbazoles |
| ES2556946T3 (es) | 2000-12-21 | 2016-01-21 | Novartis Ag | Pirimidinaminas como moduladores de la angiogénesis |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20020147198A1 (en) | 2001-01-12 | 2002-10-10 | Guoqing Chen | Substituted arylamine derivatives and methods of use |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| ES2195785B1 (es) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| US7307088B2 (en) | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| CN1688549A (zh) * | 2002-08-23 | 2005-10-26 | 麒麟麦酒株式会社 | 具有TGFβ抑制活性的化合物和含所述化合物的药用组合物 |
| US20060205790A1 (en) * | 2002-10-22 | 2006-09-14 | Coe Diane M | Medicinal arylethanolamine compounds |
| WO2005000818A1 (en) * | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| EP1714654A4 (en) * | 2004-02-09 | 2011-02-16 | Nissan Chemical Ind Ltd | MEDICAMENT FOR INHIBITING VASCULAR INTIMATE HYPERPLASIA |
| JP2008537748A (ja) * | 2005-04-06 | 2008-09-25 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| US20090227588A1 (en) * | 2005-12-05 | 2009-09-10 | Roman Wolfgang Fleck | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors |
| US20090170847A1 (en) * | 2006-01-23 | 2009-07-02 | Seung Chul Lee | Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same |
| JP2009537602A (ja) * | 2006-05-22 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 薬剤として用いるための置換ピラジノン誘導体 |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| WO2008038841A1 (en) * | 2006-09-30 | 2008-04-03 | Japan Tobacco Inc. | Thiadiazolone derivative and use thereof |
| CN102442941A (zh) * | 2006-12-14 | 2012-05-09 | 安斯泰来制药有限公司 | 用作crth2拮抗剂和抗过敏剂的多环酸化合物 |
| JP5419706B2 (ja) * | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| US8258134B2 (en) * | 2008-04-16 | 2012-09-04 | Hoffmann-La Roche Inc. | Pyridazinone glucokinase activators |
| TWI367598B (en) * | 2008-06-23 | 2012-07-01 | Ind Tech Res Inst | Antenna radome |
-
2008
- 2008-02-15 US US12/070,309 patent/US8314087B2/en active Active
- 2008-02-15 EP EP08725619A patent/EP2114898A2/en not_active Withdrawn
- 2008-02-15 AU AU2008219166A patent/AU2008219166B2/en not_active Ceased
- 2008-02-15 JP JP2009549625A patent/JP2010519204A/ja active Pending
- 2008-02-15 WO PCT/US2008/002007 patent/WO2008103277A2/en not_active Ceased
- 2008-02-15 CA CA002676173A patent/CA2676173A1/en not_active Abandoned
- 2008-02-15 MX MX2009008531A patent/MX2009008531A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2009264400B2 (en) | Novel substituted pyridin-2-ones and pyridazin-3-ones | |
| KR100922538B1 (ko) | 2,4,5-삼치환된 티아졸릴 유도체 및 그의 항염증성 활성 | |
| CN108602776B (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
| JP5490789B2 (ja) | キナーゼ阻害剤としての新規なフェニルピラジノン | |
| KR101358532B1 (ko) | 신규한 페닐이미다조피라진 | |
| KR101034489B1 (ko) | 2-아미노-4,5-삼치환 티아졸릴 유도체 | |
| JP2010533680A (ja) | 二環ヘテロアリール化合物およびそれらのキナーゼ阻害剤としての使用 | |
| JPH05503919A (ja) | 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制 | |
| JP2009530383A (ja) | Ｃｘｃｒ３拮抗活性を有する、新規ヘテロ環ピリジン置換体 | |
| JP2010535711A (ja) | 複素環式置換ピペラジンを用いる、ｃｘｃｒ３媒介性疾患の処置方法 | |
| WO2011078221A1 (ja) | イミダゾピリダジン化合物 | |
| JP2010533183A (ja) | 抗ウイルス性化合物、組成物及び使用方法 | |
| JP2022551197A5 (enExample) | ||
| WO2010081145A1 (en) | Anti-viral compounds, compositions, and methods of use | |
| US20170107214A1 (en) | 8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives | |
| WO2021115375A1 (zh) | 含氮杂环类自分泌运动因子抑制剂及其组合物和用途 | |
| JP2008509955A5 (enExample) | ||
| TW202220993A (zh) | Atr抑制劑及其用途 | |
| WO2022115384A1 (en) | Tricyclic compounds | |
| JP2021511327A5 (enExample) | ||
| JP2026503588A (ja) | 新規ａｌｐｋ１阻害剤 | |
| JP2023551139A (ja) | Ｂ型肝炎ウイルス感染症の処置および予防のためのビシクロ［１．１．１］ペンタン化合物 | |
| CA3255324A1 (en) | BICYCLE COMPOUNDS | |
| KR20180098285A (ko) | 페닐이미다졸 화합물 | |
| WO2025098425A1 (zh) | 趋化因子受体调节剂制备方法和用途 |